BRPI0515935A - pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv - Google Patents

pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv

Info

Publication number
BRPI0515935A
BRPI0515935A BRPI0515935-0A BRPI0515935A BRPI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A
Authority
BR
Brazil
Prior art keywords
alkyl
amino
optionally substituted
substituted
halo
Prior art date
Application number
BRPI0515935-0A
Other languages
English (en)
Inventor
Jerome Emile George Guillemont
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0515935A publication Critical patent/BRPI0515935A/pt
Publication of BRPI0515935B1 publication Critical patent/BRPI0515935B1/pt
Publication of BRPI0515935B8 publication Critical patent/BRPI0515935B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"PIRIMIDINAS HETEROCICLIL- OU 5-CARBO SUBSTITUìDAS PARA INIBIçãO DE HIV". Inibidores de replicação de HIV da fórmula (I), N-óxidos, sais de adição farmaceuticamente aceitáveis, aminas quaternárias ou formas estereoisoméricas dos mesmos, em que: - a¬1¬ = a¬2¬ - a¬3¬ = a¬4¬ é -CH=CH=CH=CH-, -N=CH-CH=CH, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH; -b¬1¬ = b¬2¬ - b¬3¬ = b¬4¬ é -CH=CH-CH=CH, -N=CH-CH=CH, -N=CH-N=CH, -N=CH-CH=N-, -N=N-CH=CH, -N=CH-CH=CH, -N=CH-N=CH, -N=CH-CH=N-, -N=N-CH=CH-; R¬1¬ é hidrogênio; arila; formila; C~1~ - C~6~ alquila opcionalmente substituída; C~1~ - C~6~ alquilóxicarbonila; R¬2¬ é OH; halo; C~2~-C~6~ alquinila opcionalmente substituída; carbonila substituída; carboxila; CN; nitro; amino; amino substituído; polihalometila; polihlometiltio; -S(=O)rR¬6¬; C(=NH)R¬6¬; R¬2¬ é CN;amino; amino substituído; C~1~-C~6~ alquila opcionalmente substituída; halo; C~1-6~ alquilóxi C~1-6 alquila opcionalmente substituída; C~2-6~ alquenila ou C~2-6~alquinila opcionalmente substituída; -C(=N-O-R8)-C~1-4~alquila; R¬7¬ou -X~3~-R¬7¬; X~1~ é -NR¬1¬ -, -O-, -C(=))-, CH~2~, -CHOH-, S-, -S(=O)-; R¬3¬ é CN; amino; C~1~- C~6~alquila opcionalmente substituida; -C(=N-O-R¬8¬)-C~1-4~alquila; R¬7¬; -X~3~-R¬7¬; R¬4¬ é halo; OH; C~1-6~alquila opcionalmente substituida; C~2-6~alquenila ou C~2-6~alquinila; C~3-7~ cicloalquila; C~1-6~alquilóxi; CN; nitro; polihalo C~1-6~alquila; polihalo C~1-6~alquilóxi; carbonila substituída; formila; amino; mono- ou di(C~1-4~ alquil)amino ou R¬7¬; R¬5¬ é -Y-C~q~H~2q~-L ou C~q~H~2q~-Y-C~2~H~2~r-L; L é anila ou Het; processos para o preparo desses compostos, composições farmacêuticas compreendendo esses compostos como ingredientes ativo e o uso desses compostos para a prevenção ou tratamento de infecção pelo HIV.
BRPI0515935A 2004-09-30 2005-09-29 pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica BRPI0515935B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104814 2004-09-30
PCT/EP2005/054931 WO2006035068A2 (en) 2004-09-30 2005-09-29 Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines

Publications (3)

Publication Number Publication Date
BRPI0515935A true BRPI0515935A (pt) 2008-08-12
BRPI0515935B1 BRPI0515935B1 (pt) 2019-11-19
BRPI0515935B8 BRPI0515935B8 (pt) 2021-05-25

Family

ID=34929640

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515935A BRPI0515935B8 (pt) 2004-09-30 2005-09-29 pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica

Country Status (17)

Country Link
US (1) US7531548B2 (pt)
EP (1) EP1797048B1 (pt)
JP (1) JP5162245B2 (pt)
KR (1) KR20070057798A (pt)
CN (1) CN101031550B (pt)
AR (1) AR050970A1 (pt)
AT (1) ATE520672T1 (pt)
AU (1) AU2005288865B2 (pt)
BR (1) BRPI0515935B8 (pt)
CA (1) CA2573976C (pt)
ES (1) ES2371924T3 (pt)
IL (1) IL180760A (pt)
MX (1) MX2007003798A (pt)
RU (1) RU2403244C2 (pt)
TW (1) TW200626560A (pt)
WO (1) WO2006035068A2 (pt)
ZA (1) ZA200702655B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
ES2380631T3 (es) * 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
BRPI0516746A (pt) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
JP5225079B2 (ja) 2005-06-08 2013-07-03 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
CA2645959C (en) * 2006-03-30 2016-05-17 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
JP5185283B2 (ja) * 2006-12-29 2013-04-17 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害６−置換ピリミジン
KR20090094084A (ko) * 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5,6-치환된 피리미딘
WO2008118823A2 (en) * 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN108047142B (zh) 2008-06-27 2021-08-03 西建卡尔有限责任公司 杂芳基化合物和其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2342186B1 (en) * 2009-06-22 2014-09-17 Emcure Pharmaceuticals Limited Process for synthesis of etravirine
PT2603081T (pt) 2010-08-10 2017-01-13 Celgene Avilomics Res Inc Sal de besilato de um inibidor de btk
MX2013004894A (es) 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
SI2825042T1 (sl) 2012-03-15 2019-01-31 Celgene Car Llc Soli inhibitorja kinaze receptorja faktorja epidermalne rasti
MX356753B (es) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
JOP20220188A1 (ar) 2020-02-19 2023-01-30 Pharmasyntez Joint Stock Company عوامل مضادة للفيروسات لعلاج عدوى فيروس نقص المناعة البشرية والوقاية منها
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
KR20230155351A (ko) * 2022-05-03 2023-11-10 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2024103400A1 (zh) * 2022-11-18 2024-05-23 水木未来(北京)科技有限公司 作为gpr75激活剂的多环化合物、包含其的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
CZ299380B6 (cs) 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
BRPI9909191B8 (pt) * 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
SK287269B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
ES2542326T3 (es) * 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
AU2002255452B2 (en) * 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP1565446A1 (en) * 2002-11-28 2005-08-24 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents

Also Published As

Publication number Publication date
CA2573976A1 (en) 2006-04-06
EP1797048A2 (en) 2007-06-20
BRPI0515935B1 (pt) 2019-11-19
EP1797048B1 (en) 2011-08-17
ES2371924T3 (es) 2012-01-11
TW200626560A (en) 2006-08-01
RU2403244C2 (ru) 2010-11-10
IL180760A (en) 2013-02-28
MX2007003798A (es) 2007-04-23
RU2007116161A (ru) 2008-11-10
CN101031550A (zh) 2007-09-05
BRPI0515935B8 (pt) 2021-05-25
AR050970A1 (es) 2006-12-06
KR20070057798A (ko) 2007-06-07
CN101031550B (zh) 2015-05-27
US20070208022A1 (en) 2007-09-06
ATE520672T1 (de) 2011-09-15
ZA200702655B (en) 2008-09-25
AU2005288865A1 (en) 2006-04-06
IL180760A0 (en) 2007-06-03
CA2573976C (en) 2014-04-29
WO2006035068A3 (en) 2006-08-31
WO2006035068A2 (en) 2006-04-06
JP2008514680A (ja) 2008-05-08
US7531548B2 (en) 2009-05-12
AU2005288865B2 (en) 2012-07-19
JP5162245B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
BRPI0515935A (pt) pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv
BRPI0517272A (pt) derivados de pirimidina bicìclicos de inibição de hiv
BRPI0516746A (pt) 5-heterociclil pirimidinas para inibição de hiv
PT880508E (pt) Derivados de quinazolina como inibidores de vegf
BRPI0407741A (pt) pirimidinas e triazinas de inibição de replicação de hiv
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
CA2263319A1 (en) Quinazoline derivatives and pharmaceutical compositions containing them
HRP20120351T1 (hr) Macrociklički derivati kinazolina kao antiproliferativna sredstva
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BRPI0211909B8 (pt) compostos derivados de pirimidina que inibem o hiv, processos para as suas preparações e respectiva composição farmacêutica
DE69720709D1 (de) Substituierte tetracyclische tetrahydrofuranderivate
IL159254A0 (en) Hetero-bicyclic crf antagonists
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
TW200612946A (en) Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-b]indol-2-ones and other HIV inhibitors
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
WO2002080918A1 (fr) Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
EP1330456B8 (en) N8,n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents
SE0102867D0 (sv) Non-nucleoside reverse transcriptase inhibitors
EP1747200B8 (en) Alkaloid compounds and their use as anti-malarial drugs
BRPI0511144A (pt) combinações de 1-fenil-1,5-diidro-pirido-[3,2-b]indol-2-onas substituìdas e outros inibidores de hiv
TNSN06441A1 (en) Use of phenylethanolaminotetralines for preparing anxiolytic drugs

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.